|
|
Price and reimbursement regulation of medicinal products in the Czech Republic
Němeček, Ondřej ; Lang, Roman (advisor) ; Tomšej, Jakub (referee)
Price and reimbursement regulation of medicinal products in the Czech Republic Price and reimbursement regulation of medicinal products is an integral and important part of the public health insurance system. The aim of the thesis is to describe the methods of regulation in the Czech Republic, to evaluate some of its elements and to give real examples or experiences that are known to the author of the thesis from his work experience at the State Institute for Drug Control. Apart from outlining the issues in the introduction and evaluating them in the conclusion, the thesis is divided into five chapters. The first chapter defines the basic concepts that are necessary for understanding the mechanisms of price and reimbursement regulation of medicinal products. The second chapter focuses on the historical development of price and reimbursement regulation, or the situation before and after 2008, which can undoubtedly be considered the most important milestone so far, marking the transition to the current legislation, where the maximum price and the level of reimbursement conditions are set in an administrative procedure. The third chapter then discusses price regulation, its general background and the methods of setting the maximum price. The author also describes the standard course of administrative...
|
|
|
Effectiveness of price regulation of drugs from a social point of view in the Czech Republic
Půžová, Kateřina ; Pažitný, Peter (advisor) ; Lešetický, Ondřej (referee)
The aim of this thesis is to determine the effectiveness of price regulation of drugs from a social point of view in the Czech Republic. The first part focuses on the theoretical basis for subsequent processing practical part. Theoretical solutions include a description of the objectives and instruments of health and drug policies, and a more detailed description of price regulation in the Czech Republic as a tool of drug policy. The practical part is composed of two parts. The first of them covers three models that show how you can set a maximum price of producer. This first part is the starting point for the second part. Second part deals with the analysis of administrative proceedings in which it exercised its right to express their views to the documents MAH medicine. The analysis shows that price controls are not efficient in these cases, and it burdens the society's interests. The thesis also recommendations for increasing efficiency.
|
|
|
Dopad cenové regulace léčiv v České republice a na Slovensku na postavení vybraných zájmových skupin
Musilová, Hana
Musilová, H. The impact of price regulation of drugs in the Czech republic and the Slovak republic on the status of selected interest groups. Bachelor thesis. Brno: Mendel University, 2015. The bachelor thesis deals with impact of price regulation of drugs in the Czech republic and the Slovak republic on the status of interest groups. The aim of this thesis is to describe methods of price regulation of drugs in the Czech republic and to evaluate impact of setting maximal prices of drugs. The thesis also solves the problem of parallel trade with drugs in the Czech republic, compares it with situation in Slovak republic and is looking for possible solutions to this problem.
|
|
| |
|
|
Regulation of pharmaceutical prices
Klingerová, Eliška ; Šíma, Josef (advisor) ; Durdisová, Jaroslava (referee)
This study is aimed at analyzing the effectiveness of state intervention in the form of pharmaceutical external price referencing (EPR) in selected EU countries, as well as the description of drug policy and EPR in the analyzed countries. Among the analyzed countries, the United Kingdom and Sweden have been selected as representatives who don't use EPR regulation. On the other hand, the Czech Republic, Hungary, Austria, Spain and the Netherlands are countries that regulate using EPR. The prices of selected pharmaceutical products in all of those states are converted into producer prices, on which most countries concentrate EPR. Prices are analyzed after the conversion of nominal and real exchange rates. The lowest prices are found in the Netherlands and the UK. This proves that EPR doesn't bring lower prices for medicine in the countries which use it. Further rankings vary based on the exchange rates used. The paper also analyzes the achievement of price ceilings in the Czech Republic, where the maximum prices set by regulators of EPR (including VAT) are compared with the average prices in pharmacies. All analyzed medicinal product prices are below the ceilings, which also proves the ineffectiveness of this intervention.
|
guest ::
